Stockscreener 앱 받기
9.34
0.43%
-0.04
시장 영업 전:
9.32
-0.02
-0.21%
Delcath Systems Inc 주식(DCTH)의 최신 뉴스
Risk Recap: Can CMCT reach all time highs this yearEarnings Trend Report & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Delcath Systems, Inc. (NASDAQ:DCTH) Q4 2025 earnings call transcript - MSN
Divisadero Street Capital Management LP Invests $5.12 Million in Delcath Systems, Inc. $DCTH - MarketBeat
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $250,000 from Inve - Yahoo
The Technical Signals Behind (DCTH) That Institutions Follow - Stock Traders Daily
Delcath Systems Charts Profitable Path Amid Heavy Investment - The Globe and Mail
Delcath Systems Q3 2025 Earnings Preview - MSN
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Delcath Systems (DCTH) - The Globe and Mail
Delcath Systems, Inc. (DCTH) Surpasses Q2 Earnings and Revenue Estimates - MSN
Can Delcath Systems Inc expand into new marketsQuarterly Earnings Report & Risk Managed Trade Strategies - baoquankhu1.vn
Insider Buying: Sandra Pennell Acquires Shares of Delcath Systems Inc (DCTH) - GuruFocus
Analysts Offer Insights on Healthcare Companies: CervoMed (CRVO) and Delcath Systems (DCTH) - The Globe and Mail
Fundamentals Check: Is Delcath Systems Inc a strong candidate for buy and holdMarket Performance Report & Accurate Intraday Trading Signals - baoquankhu1.vn
Propel Bio Management LLC Buys 212,457 Shares of Delcath Systems, Inc. $DCTH - MarketBeat
Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology - Yahoo Finance
HC Wainwright Lowers Earnings Estimates for Delcath Systems - MarketBeat
Delcath announces publication of liver cancer treatment trial - Investing.com
Analysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH), SOPHiA GENETICS (SOPH) and InfuSystem Holdings (INFU) - The Globe and Mail
Delcath announces publication of liver cancer treatment trial By Investing.com - Investing.com Canada
Delcath Highlights CHOPIN Phase 2 Results in Uveal Melanoma - TipRanks
Insider Buying: Gerard Michel Acquires Additional Shares of Delc - GuruFocus
CHOPIN uveal melanoma trial data in Lancet boosts Delcath (Nasdaq: DCTH) - Stock Titan
[Form 4] DELCATH SYSTEMS, INC. Insider Trading Activity - Stock Titan
Delcath Systems announces publication of Chopin clinical trial results in The Lancet Oncology - marketscreener.com
Delcath Systems, Inc. (NASDAQ:DCTH) Q4 2025 Earnings Call Transcript - Insider Monkey
Delcath Systems Announces Publication Of Chopin Clinical Trial Results In The Lancet Oncology - TradingView
Liver-directed therapy plus immunotherapy extends survival in uveal melanoma - Stock Titan
FY2029 EPS Forecast for Delcath Systems Decreased by Analyst - MarketBeat
Delcath Systems Reports Record 2025 Results, Outlines 2026 Growth Plan - National Today
Delcath: Fundamentals Intact, Despite Share Price Weakness (NASDAQ:DCTH) - Seeking Alpha
Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Uveal Melanoma Treatment Market Set to Soar: Breakthrough - openPR.com
DCTH Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Precision Trading with Delcath Systems Inc. (DCTH) Risk Zones - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Baxter International (BAX), Nautilus Biotechnolgy (NAUT) and Delcath Systems (DCTH) - The Globe and Mail
Delcath Systems (NASDAQ:DCTH) Lowered to Hold Rating by Wall Street Zen - MarketBeat
Craig-Hallum cuts Delcath Systems stock price target on revenue guide - Investing.com Canada
BTIG lowers Delcath Systems stock price target to $19 on guidance - Investing.com Australia
Delcath Systems (DCTH) First Profitable Year Tests Lofty 115.7x P/E Narrative - simplywall.st
BTIG Maintains Buy on Delcath Systems (DCTH) Feb 2026, PT Cut to $19 - Meyka
Delcath Systems Inc (DCTH) Q4 2025 Earnings Call Highlights: Rec - GuruFocus
Delcath targets at least $100M revenue in 2026 while expanding to 40 treatment centers - MSN
Delcath Systems Q4 Earnings Call Highlights - MarketBeat
Earnings Call Summary | Delcath Systems(DCTH.US) Q4 2025 Earnings Conference - 富途牛牛
DCTH: BTIG Lowers Price Target, Maintains Buy Rating for Delcath Systems | DCTH Stock News - GuruFocus
BTIG Research Cuts Delcath Systems (NASDAQ:DCTH) Price Target to $19.00 - MarketBeat
Earnings call transcript: Delcath Systems Q4 2025 sees revenue beat, stock dips - Investing.com Nigeria
Clear Street lowers Delcath Systems stock price target on revised revenue outlook - Investing.com Canada
Delcath Systems Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Delcath Systems, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Delcath (DCTH) Q4 2025 Earnings Call Transcript - AOL.com
Biliary Tract Cancer Market: Expanding Revenue Landscape to 2034 – DelveInsight | AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharma, Eisai, Merck - Barchart.com
Delcath (DCTH) Reports Strong Q4 Revenue and Anticipates Future Growth - GuruFocus
DCTH Forecasts Robust Gross Margin for Fiscal Year 2026 - GuruFocus
0.85%
1.86%
자본화:
|
볼륨(24시간):